Education
About Us
Working with TipRanks
Follow Us
Prostatype Genomics AB (DE:PGO0)
FRANKFURT:PGO0
PGO0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.06 - €0.47
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.99M
Enterprise Value€25.31M
Total Cash (Recent Filing)€11.69M
Total Debt (Recent Filing)kr666.42K
Price to Earnings (P/E)―
Beta0.43
Next Earnings
May 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding37,000,263
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.08
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PGO0 FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was €0.06 and its highest was €0.47 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €2.99M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is May 22, 2025 which is 58 days ago.
How were Prostatype Genomics AB’s earnings last quarter?
Currently, no data Available
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 37,000,263 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in DE:PGO0
Company Description
Prostatype Genomics AB
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.
Technical Analysis
Scandinavian ChemoTech AB Class B
―
Aino Health AB
―
Stayble Therapeutics AB
―
ProstaLund AB
―
Scandinavian Real Heart AB
―